Forelimb lameness associated with radiographic abnormalities of the cervical vertebrae.

Eight horses had forelimb lameness which was considered unrelated to primary forelimb pain, but was associated with radiographic abnormalities of one or more cervical vertebrae. There was no evidence of ataxia or weakness. The degree and character of the forelimb lameness varied between horses. In 4 horses, selective local analgesic techniques were used to rule out lameness associated with pain in the forelimb. In the other 4 horses, radiographic examination of the cervical region was performed on the basis of forelimb lameness seen in conjunction with neck stiffness and/or neck pain. Three horses had marked modelling of the synovial articular facet joints in the caudal cervical region; a 4th horse had modelling and a fracture involving the synovial articulation between the 4th and 5th cervical vertebrae. One horse had abnormalities of the intercentral articulation between the 7th cervical and 1st thoracic vertebrae and a discrete mineralised opacity dorsal to it. Two horses had large lucent zones in a vertebral body. One horse had a fracture of the body of the 7th cervical vertebra. Five horses were humanely destroyed, 2 returned to their previous level of activity after a prolonged period of rest and 1 was still being rested at the time of writing.

Tumor-associated trypsin inhibitor (TATI) in pleural effusions.

The purpose of this study was to evaluate the usefulness of tumor-associated trypsin inhibitor (TATI) determination in serum and pleural fluid for differential diagnosis of relapsing pleural effusions. The concentrations of TATI were determined in samples of serum and pleural fluid from 51 patients with pleural effusions comprising 20 benign exudates, 5 transudates and 26 malignant effusions. TATI levels overlapped in benign and malignant fluids. This precludes the use of this marker for diagnosis of pleural effusions. For this purpose CEA seems to be the best tumor marker with a sensitivity frequently higher than that of cytology.

Tumor-associated trypsin inhibitor (TATI) in bone diseases.

The casual observation of high serum levels in (TATI) of tumor associated trypsin inhibitor in patients with osteosarcoma inspired us to evaluate the use of this peptide in the diagnosis of various bone diseases. We determined the serum concentrations of TATI in 35 patients with various bone diseases, i.e. degenerative diseases, bone metastasis and osteosarcomas. The cut off, determined as the 99th percentile of TATI serum levels in healthy volunteers was 32 micrograms/l. TATI has a better sensitivity in osteosarcomas (83%) than in metastatic bone diseases (33%). Its specificity in non-malignant bone diseases was not exceptional (82%). This is probably because TATI may also behave as on acute phase protein, the levels of which can rise in non-malignant diseases and also as a result of a tissue reaction in primary bone tumors.